Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Current Assets (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Current Assets for 3 consecutive years, with $241.5 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Current Assets fell 28.2% year-over-year to $241.5 million, compared with a TTM value of $241.5 million through Sep 2021, down 28.2%, and an annual FY2020 reading of $319.6 million, up 105.22% over the prior year.
  • Current Assets was $241.5 million for Q3 2021 at Black Diamond Therapeutics, down from $270.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $362.1 million in Q1 2020 and bottomed at $155.7 million in Q4 2019.
  • Average Current Assets over 3 years is $274.0 million, with a median of $284.1 million recorded in 2021.
  • The sharpest move saw Current Assets skyrocketed 105.22% in 2020, then fell 28.2% in 2021.
  • Year by year, Current Assets stood at $155.7 million in 2019, then surged by 105.22% to $319.6 million in 2020, then fell by 24.41% to $241.5 million in 2021.
  • Business Quant data shows Current Assets for BDTX at $241.5 million in Q3 2021, $270.9 million in Q2 2021, and $297.3 million in Q1 2021.